# A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

> **NCT06499350** · PHASE1,PHASE2 · RECRUITING · sponsor: **FindCure Biosciences (ZhongShan) Co., Ltd.** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** FC084CSA+Tislelizumab combination (dose escalation)
- **DRUG:** RP2D of FC084CSA+Tislelizumab combination (dose expansion)

## Key facts

- **NCT ID:** NCT06499350
- **Lead sponsor:** FindCure Biosciences (ZhongShan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06499350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06499350, "A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06499350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*